The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 22nd Oct 2014 09:54

Amino Technologies: N+1 Singer moves target price from 93p to 107p upgrading to buy.Anglo American: Liberum Capital reduces target price from 1300p to 1200p retaining its sell recommendation.ARM Holdings: UBS moves target price from 970p to 980p upgrading from neutral to buy. Deutsche Bank cuts target price from 950p to 900p and retains a hold recommendation.Ashmore Group: Liberum Capital upgrades to hold with a target price of 285p.ASOS: Liberum Capital cuts target price from 1440p to 1400p maintaining its sell recommendation.BP: Credit Suisse lowers target price from 505p to 470p staying with its neutral rating.Countrywide: Panmure Gordon reduces target price from 700p to 565p keeping a buy recommendation.Darty: Societe Generale cuts target price from 124p to 97.5p, while leaving its buy recommendation unchanged.Ferrexpo: Liberum Capital downgrades to sell.GKN: Canaccord Genuity cuts target price from 500p to 450p and reiterates a buy recommendation. Barclays cuts target price from 440p to 390p and keeps an overweight rating.GlaxoSmithKline: Panmure Gordon reduces target price from 1600p to 1425p staying with its hold recommendation.International Personal Finance: Panmure Gordon raises target price from 400p to 540p and upgrades from sell to buy.Kingfisher: Deutsche Bank lowers target price from 415p to 400p and keeps a buy recommendation.Playtech: Numis ups target price from 665p to 720p and reiterates a hold recommendation.Reckitt Benckiser: Numis cuts target price from 5600p to 5548p, while upgrading from hold to add.Royal Dutch Shell: Credit Suisse reduces target price from 2700p to 2625p and keeps an outperform rating.Senior: Numis downgrades from buy to add with a target price of 315p.Shire: Deutsche Bank raises target price from 4350p to 4550p and maintains a buy recommendation.Shoe Zone: Numis ups target price from 215p to 250p keeping a buy recommendation.Spirit Pub: Panmure Gordon downgrades from buy to hold with a target price of 110p. Shore downgrades from buy to hold.StratMin Global Resources: Northland lowers target price from 19.6p to 19.3p, while upgrading from hold to buy.Super Group: Investec reduces target price from 1500p to 1420p maintaining a buy recommendation.Travis Perkins: Liberum Capital cuts target price from 2100p to 2050p and retains a buy recommendation.Unite Group: JP Morgan ups target price from 475p to 495p and maintains an overweight rating.
More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.